US 10,376,504 B2
Substituted quinolinones as PDE9 inhibitors
Antonella Converso, Elkins Park, PA (US); and Kevin Rodzinak, Valdosta, GA (US)
Assigned to Merck, Sharp & Dohme Corp., Rahway, NJ (US)
Appl. No. 15/745,838
Filed by Merck Sharp & Dohme Corp., Rahway, NJ (US)
PCT Filed Jul. 27, 2016, PCT No. PCT/US2016/044161
§ 371(c)(1), (2) Date Jan. 18, 2018,
PCT Pub. No. WO2017/019723, PCT Pub. Date Feb. 2, 2017.
Claims priority of provisional application 62/198,507, filed on Jul. 29, 2015.
Prior Publication US 2018/0214439 A1, Aug. 2, 2018
Int. Cl. A61K 31/4704 (2006.01); C07D 215/227 (2006.01); A61K 31/4709 (2006.01); C07D 401/14 (2006.01); C07D 215/54 (2006.01); C07D 401/02 (2006.01); C07D 405/12 (2006.01); A61P 25/14 (2006.01); A61P 25/18 (2006.01); A61K 31/277 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/4545 (2006.01); A61K 31/55 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 31/277 (2013.01); A61P 25/14 (2018.01); A61P 25/18 (2018.01); C07D 215/54 (2013.01); C07D 401/02 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/4545 (2013.01); A61K 31/55 (2013.01)] 2 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising an inert carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.